MA53418B1 - Préparation d'absorption transdermique contenant du donépézil stabilisé - Google Patents
Préparation d'absorption transdermique contenant du donépézil stabiliséInfo
- Publication number
- MA53418B1 MA53418B1 MA53418A MA53418A MA53418B1 MA 53418 B1 MA53418 B1 MA 53418B1 MA 53418 A MA53418 A MA 53418A MA 53418 A MA53418 A MA 53418A MA 53418 B1 MA53418 B1 MA 53418B1
- Authority
- MA
- Morocco
- Prior art keywords
- donepezil
- transdermal absorption
- absorption preparation
- preparation containing
- layer
- Prior art date
Links
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 title abstract 14
- 229960003530 donepezil Drugs 0.000 title abstract 7
- 238000010521 absorption reaction Methods 0.000 title abstract 6
- 206010012289 Dementia Diseases 0.000 abstract 3
- 229940079593 drug Drugs 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- VLCDUOXHFNUCKK-UHFFFAOYSA-N N,N'-Dimethylthiourea Chemical compound CNC(=S)NC VLCDUOXHFNUCKK-UHFFFAOYSA-N 0.000 abstract 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000000853 adhesive Substances 0.000 abstract 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 abstract 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La présente invention concerne une préparation d'absorption transdermique pour le traitement de la démence contenant du donépézil et, plus précisément, une préparation d'absorption transdermique pour le traitement de la démence contenant du donépézil, la préparation d'absorption transdermique contenant du donépézil étant constituée d'une couche de support, d'une couche contenant un médicament, et d’une couche de libération, la couche contenant un médicament contenant du donépézil ou un sel pharmaceutiquement acceptable de celui-ci en tant que principe actif, du monothioglycérol, du thiocyanate (de manière appropriée, du sel de potassium) ou de la diméthylthiourée en tant que stabilisant, et un agent adhésif. La préparation d'absorption transdermique pour traiter la démence selon la présente invention fournit une préparation d'absorption transdermique contenant du donépézil qui peut réduire la production de substances apparentées au donépézil.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020180167289A KR102115102B1 (ko) | 2018-12-21 | 2018-12-21 | 안정화된 도네페질 함유 경피 흡수제제 |
| PCT/KR2019/011483 WO2020130287A1 (fr) | 2018-12-21 | 2019-09-05 | Préparation d'absorption transdermique contenant du donépézil stabilisé |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA53418A1 MA53418A1 (fr) | 2022-08-31 |
| MA53418B1 true MA53418B1 (fr) | 2023-03-31 |
Family
ID=70914737
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA53418A MA53418B1 (fr) | 2018-12-21 | 2019-09-05 | Préparation d'absorption transdermique contenant du donépézil stabilisé |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US12168073B2 (fr) |
| EP (1) | EP3900711B1 (fr) |
| JP (1) | JP7193643B2 (fr) |
| KR (1) | KR102115102B1 (fr) |
| CN (1) | CN113260356B (fr) |
| AU (1) | AU2019405846B2 (fr) |
| BR (1) | BR112021012142A2 (fr) |
| CA (1) | CA3124070C (fr) |
| CL (1) | CL2021001463A1 (fr) |
| ES (1) | ES2972123T3 (fr) |
| MA (1) | MA53418B1 (fr) |
| MX (1) | MX2021007078A (fr) |
| PE (1) | PE20211791A1 (fr) |
| PH (1) | PH12021551453A1 (fr) |
| PL (1) | PL3900711T3 (fr) |
| WO (1) | WO2020130287A1 (fr) |
| ZA (1) | ZA202104943B (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102218593B1 (ko) * | 2020-05-13 | 2021-02-22 | 동아에스티 주식회사 | 안정성이 향상된 도네페질 함유 경피 흡수제제 |
| JP2022122784A (ja) * | 2021-02-10 | 2022-08-23 | コスメディ製薬株式会社 | 酸化防止剤含有経皮吸収製剤 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS609727B2 (ja) * | 1980-09-27 | 1985-03-12 | 日東電工株式会社 | 貼り付け用膏体 |
| US5146730A (en) | 1989-09-20 | 1992-09-15 | Banner Gelatin Products Corp. | Film-enrobed unitary-core medicament and the like |
| ATE254928T1 (de) | 1999-03-31 | 2003-12-15 | Eisai Co Ltd | Stabilisierte zusammensetzung mit nootropen wirkstoffen |
| WO2003032960A1 (fr) | 2001-10-17 | 2003-04-24 | Hisamitsu Pharmaceutical Co., Inc. | Preparations pour absorption percutanee |
| MX2007007836A (es) | 2004-12-27 | 2007-08-20 | Eisai R&D Man Co Ltd | Metodo para estabilizar un farmaco anti-demencia. |
| US20080138388A1 (en) | 2005-02-04 | 2008-06-12 | Hisamitsu Pharmaceutical Co., Inc. | Transdermal Absorption Patch |
| EP2638906A1 (fr) * | 2006-12-01 | 2013-09-18 | Nitto Denko Corporation | Préparation d'adhésif cutané comprenant du donépézil stabilisé |
| RU2452474C2 (ru) * | 2006-12-01 | 2012-06-10 | Нитто Денко Корпорейшн | Стабилизированная адгезивная композиция, содержащая донепезил |
| CA2670995A1 (fr) | 2006-12-01 | 2008-06-05 | Nitto Denko Corporation | Preparation adhesive pour la peau comprenant du donepezil stabilise |
| US20100062045A1 (en) * | 2006-12-01 | 2010-03-11 | Nitto Denko Corporation | Method for suppressing coloring of adhesive prepartion containing donepezil and method for reducing amounts of donepezil-related substances formed |
| KR101454362B1 (ko) | 2008-03-24 | 2014-10-23 | 아이큐어 주식회사 | 도네페질을 유효성분으로 함유하는 치매 치료용경피흡수제제 |
| US20090291127A1 (en) | 2008-05-21 | 2009-11-26 | Jianye Wen | Transdermal anti-dementia active agent formulations and methods for using the same |
| BR112012011334A2 (pt) | 2009-10-21 | 2020-08-25 | Teikoku Seiyaku Co., Ltd. | formulação transdermicamente absorvível contendo donepezil |
| CN102614109B (zh) * | 2012-04-16 | 2013-11-13 | 上海现代药物制剂工程研究中心有限公司 | 基于多层液晶骨架的、含有活性物质的凝胶组合物及制法 |
| KR101770675B1 (ko) | 2013-01-30 | 2017-08-23 | 에스케이케미칼주식회사 | 도네페질-함유 경피흡수제제 및 그의 제조방법 |
| KR101485822B1 (ko) | 2014-01-22 | 2015-01-23 | 주식회사 대웅제약 | 도네페질 또는 그의 염을 함유하는 경피흡수제제 |
| KR20160120778A (ko) | 2014-02-20 | 2016-10-18 | 날 파마슈티칼 그룹 리미티드 | 도네페질을 함유하는 경피흡수제제 |
| CN106714787A (zh) * | 2014-09-25 | 2017-05-24 | 富士胶片株式会社 | 含丙泊酚的水包油型乳液组合物及其制造方法 |
| CN107106510A (zh) | 2014-12-18 | 2017-08-29 | Icure药品株式会社 | 含有多奈哌齐为有效成分的经皮吸收制剂 |
| ES2805342T3 (es) * | 2015-10-26 | 2021-02-11 | Hisamitsu Pharmaceutical Co | Parche cutáneo adhesivo |
| US20180008612A1 (en) | 2016-07-11 | 2018-01-11 | Taho Pharmaceuticals Ltd. | Transdermal delivery system containing galantamine or salts thereof |
| CN116270551A (zh) | 2016-07-27 | 2023-06-23 | 考里安有限责任公司 | 通过盐至中性药物原位转化的组合物、透皮贴剂及应用 |
| KR102024996B1 (ko) | 2017-12-27 | 2019-09-25 | 동아에스티 주식회사 | 도네페질을 함유하는 치매 치료용 경피흡수제제 |
| SG11202101309WA (en) | 2018-08-31 | 2021-03-30 | Arctic Therapeutics Llc | Novel topical formulation for intradermal application and uses thereof |
-
2018
- 2018-12-21 KR KR1020180167289A patent/KR102115102B1/ko active Active
-
2019
- 2019-09-05 PL PL19897865.2T patent/PL3900711T3/pl unknown
- 2019-09-05 JP JP2021535228A patent/JP7193643B2/ja active Active
- 2019-09-05 ES ES19897865T patent/ES2972123T3/es active Active
- 2019-09-05 PE PE2021001051A patent/PE20211791A1/es unknown
- 2019-09-05 US US17/416,930 patent/US12168073B2/en active Active
- 2019-09-05 CN CN201980083837.8A patent/CN113260356B/zh active Active
- 2019-09-05 EP EP19897865.2A patent/EP3900711B1/fr active Active
- 2019-09-05 BR BR112021012142-0A patent/BR112021012142A2/pt unknown
- 2019-09-05 WO PCT/KR2019/011483 patent/WO2020130287A1/fr not_active Ceased
- 2019-09-05 PH PH1/2021/551453A patent/PH12021551453A1/en unknown
- 2019-09-05 CA CA3124070A patent/CA3124070C/fr active Active
- 2019-09-05 AU AU2019405846A patent/AU2019405846B2/en active Active
- 2019-09-05 MA MA53418A patent/MA53418B1/fr unknown
- 2019-09-05 MX MX2021007078A patent/MX2021007078A/es unknown
-
2021
- 2021-06-03 CL CL2021001463A patent/CL2021001463A1/es unknown
- 2021-07-14 ZA ZA2021/04943A patent/ZA202104943B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3900711A4 (fr) | 2022-11-30 |
| CA3124070A1 (fr) | 2020-06-25 |
| ZA202104943B (en) | 2022-08-31 |
| KR102115102B1 (ko) | 2020-05-26 |
| MX2021007078A (es) | 2021-09-10 |
| PH12021551453A1 (en) | 2022-04-18 |
| CL2021001463A1 (es) | 2021-12-10 |
| JP7193643B2 (ja) | 2022-12-20 |
| EP3900711A1 (fr) | 2021-10-27 |
| JP2022514037A (ja) | 2022-02-09 |
| BR112021012142A2 (pt) | 2021-09-08 |
| CN113260356A (zh) | 2021-08-13 |
| PL3900711T3 (pl) | 2024-07-22 |
| EP3900711B1 (fr) | 2024-03-06 |
| AU2019405846B2 (en) | 2022-10-20 |
| CN113260356B (zh) | 2024-09-17 |
| ES2972123T3 (es) | 2024-06-11 |
| EP3900711C0 (fr) | 2024-03-06 |
| US20220047524A1 (en) | 2022-02-17 |
| AU2019405846A1 (en) | 2021-06-17 |
| PE20211791A1 (es) | 2021-09-09 |
| MA53418A1 (fr) | 2022-08-31 |
| US12168073B2 (en) | 2024-12-17 |
| CA3124070C (fr) | 2024-03-12 |
| WO2020130287A1 (fr) | 2020-06-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lee et al. | Endothelial progenitor cells in cardiovascular diseases | |
| Lau et al. | Boldine protects endothelial function in hyperglycemia-induced oxidative stress through an antioxidant mechanism | |
| SA522433129B1 (ar) | مركب بيريدازينيل-ثيازول كربوكساميد | |
| CL2010001467A1 (es) | Compuestos derivados de fenil-imidazol sustituido con un heteroaromatico biciclico; composicion farmaceutica que los comprende; y su uso como inhibidores de la pde10a para tratar trastornos neurodegenerativos o psiquiatricos como alzheimer, demencia alcoholica, trastorno del aprendizaje, esquizofrenia, adiccion a las drogas. | |
| MA38698B1 (fr) | Système d'administration transdermique | |
| EA200701036A1 (ru) | Лактамные соединения и их применение в качестве фармацевтических препаратов | |
| MA40768B1 (fr) | Dérivés d'indole mono ou di-substitué en tant qu'inhibiteurs de réplication du virus de la dengue | |
| MA42811B1 (fr) | Dérivés d'indole monosubstitués ou disubstitués utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue | |
| EP3699174A4 (fr) | Composition pour la prévention ou le traitement de maladies liées au tnf, contenant un nouveau dérivé en tant que principe actif, et procédé d'inhibition de l'activité du tnf à l'aide de celle-ci | |
| BR112020016331A8 (pt) | Métodos para tratar câncer com anticorpos anti-pd-1 | |
| MA40769A (fr) | Indoles mono ou di-substitués utilisés en tant qu'inhibiteurs de réplication du virus de la dengue | |
| MA33593B1 (fr) | Composés hétérocycliques et leurs utilisations | |
| MA56661B1 (fr) | Formes cristallines de 7-chloro-2-(4-(3-méthoxyazétidine-1-yl))cyclohexyl) 2,4-diméthyl-n-((6-méthyl-4-(méthylthio)-2-oxo-1,2-dihydropyridine-3-yl) méthyl)benzo[d][1,3]dioxole-5-carboxamide | |
| CR20190433A (es) | Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1 | |
| ATE534293T1 (de) | Diarylaminhaltige verbindungen und zusammensetzungen und deren verwendung als modulatoren von c-kit-rezeptoren | |
| PE20200740A1 (es) | Analogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton | |
| EP3838898C0 (fr) | Dérivé d'isoindolin-1-one, procédé de préparation de celui-ci, et composition pharmaceutique le contenant en tant que composant actif pour la prévention ou le traitement du cancer | |
| MA53418B1 (fr) | Préparation d'absorption transdermique contenant du donépézil stabilisé | |
| MA38694B1 (fr) | Dérivés thérapeutiquement actifs d'estratriène-thiazole à substitution azote en position 17 en tant qu'inhibiteurs de la 17bêta.-hydroxystéroïde déshydrogénase | |
| JOP20220160A1 (ar) | مركبات فعّالة نحو مستقبلات نووية | |
| EP3760626A4 (fr) | Nouveau composé et composition pour la prévention, l'amélioration ou le traitement de la fibrose ou de la stéatohépatite non alcoolique le comprenant en tant que principe actif | |
| MA46268B1 (fr) | Dérivés de 5-[2-(pyridin-2-ylamino)-1 ,3-thiazol-5-yl]-2,3-dihydro-1h-isoindol-1-one et leur utilisation en tant qu'inhibiteurs doubles de phosphatidylinositol 3-kinase delta & gamma | |
| CO5190664A1 (es) | Terapia de combinacion para el tratamiento de migrana administracion de un receptor 5ht, cafeina y un inhibidor de ciclooxigenasa-2 | |
| EP4159235A4 (fr) | Composition pharmaceutique contenant un agoniste de pd-1 pour traiter ou prévenir une maladie médiée par th2 | |
| EP4005572A4 (fr) | Dérivé de benzamide, son procédé de préparation, et composition pharmaceutique le comprenant en tant que principe actif pour la prévention ou le traitement du cancer |